Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.
Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.
Benjamin Lowentritt share...